Abeona Therapeutics (NASDAQ:ABEO) Coverage Initiated at StockNews.com

Research analysts at StockNews.com started coverage on shares of Abeona Therapeutics (NASDAQ:ABEOGet Rating) in a report issued on Wednesday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

NASDAQ:ABEO opened at $0.19 on Wednesday. The firm has a 50-day moving average price of $0.18 and a two-hundred day moving average price of $0.27. Abeona Therapeutics has a twelve month low of $0.13 and a twelve month high of $1.75. The company has a market capitalization of $27.44 million, a P/E ratio of -0.23 and a beta of 1.51.

Abeona Therapeutics (NASDAQ:ABEOGet Rating) last posted its earnings results on Friday, May 13th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.02). The business had revenue of $0.35 million for the quarter. As a group, sell-side analysts predict that Abeona Therapeutics will post -0.28 EPS for the current year.

Several hedge funds and other institutional investors have recently modified their holdings of ABEO. Franklin Resources Inc. purchased a new stake in shares of Abeona Therapeutics during the third quarter worth about $364,000. Assenagon Asset Management S.A. boosted its position in shares of Abeona Therapeutics by 876.7% in the fourth quarter. Assenagon Asset Management S.A. now owns 3,127,813 shares of the biopharmaceutical company’s stock worth $1,054,000 after acquiring an additional 2,807,578 shares during the last quarter. BNP Paribas Arbitrage SA boosted its position in shares of Abeona Therapeutics by 1,166,274.8% in the fourth quarter. BNP Paribas Arbitrage SA now owns 1,854,536 shares of the biopharmaceutical company’s stock worth $625,000 after acquiring an additional 1,854,377 shares during the last quarter. AIGH Capital Management LLC acquired a new stake in shares of Abeona Therapeutics in the fourth quarter worth approximately $383,000. Finally, Acadian Asset Management LLC acquired a new stake in shares of Abeona Therapeutics in the fourth quarter worth approximately $78,000. Institutional investors and hedge funds own 27.81% of the company’s stock.

About Abeona Therapeutics (Get Rating)

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.

Read More

Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Abeona Therapeutics (NASDAQ:ABEO) Coverage Initiated at StockNews.com

Research analysts at StockNews.com started coverage on shares of Abeona Therapeutics (NASDAQ:ABEOGet Rating) in a report issued on Wednesday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

NASDAQ:ABEO opened at $0.19 on Wednesday. The firm has a 50-day moving average price of $0.18 and a two-hundred day moving average price of $0.27. Abeona Therapeutics has a twelve month low of $0.13 and a twelve month high of $1.75. The company has a market capitalization of $27.44 million, a P/E ratio of -0.23 and a beta of 1.51.

Abeona Therapeutics (NASDAQ:ABEOGet Rating) last issued its quarterly earnings results on Friday, May 13th. The biopharmaceutical company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.02). The firm had revenue of $0.35 million for the quarter. As a group, sell-side analysts predict that Abeona Therapeutics will post -0.28 EPS for the current year.

Several hedge funds and other institutional investors have recently modified their holdings of ABEO. Franklin Resources Inc. purchased a new stake in shares of Abeona Therapeutics during the third quarter worth about $364,000. Assenagon Asset Management S.A. boosted its position in shares of Abeona Therapeutics by 876.7% in the fourth quarter. Assenagon Asset Management S.A. now owns 3,127,813 shares of the biopharmaceutical company’s stock worth $1,054,000 after acquiring an additional 2,807,578 shares during the last quarter. BNP Paribas Arbitrage SA boosted its position in shares of Abeona Therapeutics by 1,166,274.8% in the fourth quarter. BNP Paribas Arbitrage SA now owns 1,854,536 shares of the biopharmaceutical company’s stock worth $625,000 after acquiring an additional 1,854,377 shares during the last quarter. AIGH Capital Management LLC acquired a new stake in shares of Abeona Therapeutics in the fourth quarter worth approximately $383,000. Finally, Acadian Asset Management LLC acquired a new stake in shares of Abeona Therapeutics in the fourth quarter worth approximately $78,000. Institutional investors and hedge funds own 27.81% of the company’s stock.

About Abeona Therapeutics (Get Rating)

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.

Read More

Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.